Wegovy and Ozempic are both weight loss drugs that belong to the GLP-1 agonist class. Wegovy is a relatively new drug that was approved by the FDA in June 2021, while Ozempic has been on the market since December 2017.

According to Drug Patent Watch [1], Wegovy's patent will expire in 2038, which means that no generic version of the drug will be available until then. On the other hand, Ozempic's patent is set to expire in 2030, which means that a generic version of the drug may become available after that date.

When it comes to the cost of these drugs, GoodRx [2] states that the average retail price of Wegovy is around $1,300 for a 4-week supply, while the average retail price of Ozempic is around $1,400 for a 4-week supply. However, the actual cost of these drugs may vary depending on factors such as insurance coverage and pharmacy discounts.

NBC News [3] reports that the demand for both Wegovy and Ozempic has been soaring since their approval, with many people looking for effective weight loss solutions. However, it is worth noting that these drugs are not suitable for everyone and should only be taken under the guidance of a healthcare professional.

In conclusion, based on the provided sources, Wegovy and Ozempic have similar retail prices, with Wegovy having a longer patent life. However, the actual cost of these drugs may vary depending on insurance coverage and pharmacy discounts. It is important to consult with a healthcare professional to determine which drug is the most suitable and cost-effective option for an individual's weight loss needs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.goodrx.com/classes/glp-1-agonists/wegovy-vs-ozempic
[3] https://www.nbcnews.com/health/health-news/ozempic-wegovy-weight-loss-drugs-demand-soars-rcna68425